Literature DB >> 2115297

Pharmacokinetics of gestagens: some problems.

K Fotherby1.   

Abstract

Various approaches to studying the pharmacokinetics of gestagens and the factors that influence derivation of the parameters are described with levonorgestrel used as an example. Published studies of the pharmacokinetics of levonorgestrel are reviewed, and new information is presented regarding intra- and intersubject variation. Differences between various formulations of levonorgestrel are apparent when the formulations are compared in the same subjects. There is also a marked difference in the parameters when derived under single-dose or steady-state conditions. The role of sex hormone-binding globulin in the metabolism of levonorgestrel is questioned. Large intra- and inter-subject variations in the parameters exist, and a subject may show a large month-to-month variation when one levonorgestrel formulation is used and smaller variations when another formulation is used. This wide variability in the pharmacokinetic parameters, problems that arise in the derivation and interpretation of the parameters, the biologic significance of most of these parameters, and their lack of correlation with pharmacodynamic responses severely limit the usefulness of pharmacokinetic studies of the gestagens.

Entities:  

Keywords:  Biology; Contraception; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Female--pharmacodynamics; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents, Progestin--pharmacodynamics; Contraceptive Agents--administraction and dosage; Contraceptive Agents--pharmacodynamics; Contraceptive Methods; Demographic Factors; Endocrine System; Estrogens--pharmacodynamics; Family Planning; Hormones; Levonorgestrel--administraction and dosage; Levonorgestrel--pharmacodynamics; Literature Review; Oral Contraceptives; Physiology; Population; Population Dynamics; Time Factors

Mesh:

Substances:

Year:  1990        PMID: 2115297     DOI: 10.1016/0002-9378(90)90576-s

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

1.  Estimating systemic exposure to levonorgestrel from an oral contraceptive.

Authors:  Cale N Basaraba; Carolyn L Westhoff; Malcolm C Pike; Renu Nandakumar; Serge Cremers
Journal:  Contraception       Date:  2016-12-30       Impact factor: 3.375

Review 2.  Perspectives on variability in pharmacokinetics of an oral contraceptive product.

Authors:  William J Jusko
Journal:  Contraception       Date:  2016-07-27       Impact factor: 3.375

Review 3.  Levonorgestrel. Clinical pharmacokinetics.

Authors:  K Fotherby
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

4.  Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users.

Authors:  Alison B Edelman; Ganesh Cherala; Myrna Y Munar; Barent Dubois; Martha McInnis; Frank Z Stanczyk; Jeffrey T Jensen
Journal:  Contraception       Date:  2012-11-12       Impact factor: 3.375

5.  Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity.

Authors:  Alison B Edelman; Nichole E Carlson; Ganesh Cherala; Myrna Y Munar; Richard L Stouffer; Judy L Cameron; Frank Z Stanczyk; Jeffrey T Jensen
Journal:  Contraception       Date:  2009-06-04       Impact factor: 3.375

6.  Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial.

Authors:  Alison B Edelman; Ganesh Cherala; Myrna Y Munar; Martha McInnis; Frank Z Stanczyk; Jeffrey T Jensen
Journal:  Contraception       Date:  2014-06-27       Impact factor: 3.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.